Trials / Completed
CompletedNCT02102750
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Santen Oy · Industry
- Sex
- All
- Age
- 1 Month – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to examine how preservative free tafluprost ophthalmic solution (0.0015%) is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Preservative free tafluprost opthalmic solution | 0.0015% eye drops q.d, in both eyes for 7 to 9 days |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-05-29
- Completion
- 2017-07-03
- First posted
- 2014-04-03
- Last updated
- 2017-10-10
Locations
2 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT02102750. Inclusion in this directory is not an endorsement.